What did the Rakesh Jhunjhunwala Portfolio look like?

21 November 2022
3 mins read
One of the stalwart investors in the Indian stock market, Mr. Rakesh Jhunjhunwala left a legacy through his choice of investments - something that every investor can and should learn from.
What did the Rakesh Jhunjhunwala Portfolio look like?

Short history of Rakesh Jhunjhunwala

Rakesh Jhunjhunwala (5th July 1960 – 14th August 2022) was an Indian billionaire (and Chartered Accountant) who had grown rich majorly from his stock market investments. His journey in the stock market began in 1985 with a mere ₹5000 and by the time of his death, he had gained a net worth of around $5.8 billion. He was often referred to as the “India’s Warren Buffet” or the “Big Bull of India” as he was known for his bullish stances – sometimes buying penny stocks as well. He managed his own portfolio as a partner in his firm Rare Enterprises. 

He tended to prefer investments in finance, tech, pharmaceuticals and retail industries. Rakesh Jhunjhunwala and Associates portfolio currently consists of 30 stocks which in total are worth over ₹ 34,320.2 cr.

Portfolio of Rakesh Jhunjhunwala and Associates

As of September 2022, the top 10 stocks in the portfolio of Rakesh Jhunjhunwala and Associates stood as the following:

Name of the Company Total value of the holding (in ₹) Number of shares held
Titan Company Ltd. 13,047.1 Cr 4,92,00,970
Star Health and Allied Insurance Company Ltd. 6,982.8 Cr 10,07,53,935
Metro Brands Ltd. 3,130.5 Cr 3,91,53,600
Tata Motors Ltd. 1,556.4 Cr 3,67,50,000
Crisil Ltd. 1,193.4 Cr 40,00,000
Fortis Healthcare Ltd. 992.2 Cr 3,51,52,108
Indian Hotels Company Ltd. 946.6 Cr 3,00,16,965
Canara Bank 817.4 Cr 2,68,47,400
Federal Bank Ltd. 739.0 Cr 5,47,21,060
Aptech Ltd. 639.5 Cr 1,81,12,312

Note: All figures above are only temporary as share prices (and consequently, shareholding values) keep changing

Top holdings of the Rakesh Jhunjhunwala Portfolio

Below are the top 5 holdings of Rakesh Jhunjhunwala and Associates as of September 2022:

S.No.  Name of the Stock Total value (in ₹) Number of shares held % of the company held (Sep’22) % of the company held (Jun’22)
1 Titan Company Ltd. 13,047.1 Cr 4,92,00,970 5.50% 5.10%
2 Star Health and Allied Insurance Company Ltd. 6,982.8 Cr 10,07,53,935 17.40% 17.50%
3 Metro Brands Ltd. 3,130.5 Cr 3,91,53,600 14.40% 14.40%
4 Tata Motors Ltd. 1,556.4 Cr 3,67,50,000 1.10% 1.10%
5 Crisil Ltd. 1,193.4 Cr 40,00,000 5.50% 5.50%

Note: All figures above are only temporary as share prices (and consequently, shareholding values) keep changing

In the quarter ending in September 2022, the holding of Rakesh Jhunjhunwala and Associates had increased by 0.5% in Titan Co. Ltd. and decreased by 0.1% in Star Health and Allied Insurance Co. Ltd.

Final words

If you are thinking about buying any of the stocks mentioned above in the Rakesh Jhunjhunwala portfolio, but do not know how to begin, try reading up more about the stock market. If you do not have a demat account, try opening one today in a matter of minutes.

FAQs

Who is Rakesh Jhunjhunwala?

Rakesh Jhunjhunwala was one of the biggest stock market investors in India. At the time of his death, Rakesh Jhunjhunwala had a portfolio of 32 stocks worth over ₹31,904.8 cr.

What is the biggest stock in Rakesh Jhunjhunwala portfolio?

In terms of value, Rakesh Jhunjhunwala’s biggest holding was in Titan Company Ltd. – it is currently worth over ₹13,047.1 Cr.

What was Rakesh Jhunjhunwala’s last big investment?

One of Rakesh Jhunjhunwala’s last big investments was in Akasa Air (India’s newest airline) of which he had bought around 40% at almost ₹250 cr.

How did Rakesh Jhunjhunwala die?

Rakesh Jhunjhunwala died of cardiac arrest on 14th August 2022 at the age of 62.

What stock gave Rakesh Jhunjhunwala his first big profit?

Rakesh Jhunjhunwala made his first big profit from 5000 shares of Tata Tea in 1985 – his capital was tripled in three months in that investment.

Disclaimer: This blog is exclusively for educational purposes. The securities quoted are exemplary and are not recommendatory.